Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases

Completed · Not applicable

Conditions studied: Hematological Neoplasms, Hematopoietic Stem Cell Transplantation

In brief

To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases

Key facts

Study ID

NCT00582894

Run by

University of Oklahoma

People needed

17

Starts

2005-02-01

Expected to finish

2008-03-01

Last updated by the study team

2011-04-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Performance status 0-2
• Ejection fraction > 30%
• AST/ALT and bilirubin not > 4 times normal
• Creatinine clearance greater than 70 ml/min.
• FEV1 greater than 1.0 and diffusion capacity greater than 40%
• Age 18-75 years
• Patients must be at high risk for conventional regimen related toxicity
• Malignant hematologic disease that would otherwise be considered treatable with ASCT

You may not qualify if…

• Does not meet the above Inclusion criteria

Where it is running

• University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.